Proactive Investors - Run By Investors For Investors
Why invest in REDX?
Redx Pharma Plc: DEEP DIVE
OVERVIEW

Redx Pharma: Developing treatments for cancer and fibrosis

Its lead asset, RXC004, is part of a potentially breakthrough group of cancer drugs called Porcupine inhibitors
researcher at microscope
OVERVIEW: REDX The Big Picture
The cancer drug is in the clinic, while a fibrosis treatment should be ready to enter the clinic a year from now
  • Cancer drug in the clinic 
  • Promising fibrosis treatments targeting large markets

What the company does 

Redx Pharma Plc (LON:REDX) is an early-stage drug developer that is bringing through treatments for cancer and fibrosis.

Its lead asset, RXC004, is part of a potentially breakthrough group of cancer drugs called Porcupine inhibitors. They work by dialling down the Porcupine protein, which is the control switch for the Wnt pathway – known to be heavily involved in cell growth and division. Now, not all cancers are driven by the Wnt pathway, but the hope is that RXC004 will inhibit the growth of those which are.

Interestingly, there’s a growing bank of research that suggests Porcupine inhibitors may also be very effective in tandem with checkpoint inhibitors such as anti-PD-1s, which lower or break cancer’s defence against the body’s immune system. That’s why Redx plans to assess the drug in combination with a checkpoint inhibitor further down the line, something Swiss giant Novartis is doing with its Porcupine inhibitors.

In parallel it is developing potential fibrosis treatments. RXC006 is designed to tackle a condition called idiopathic pulmonary fibrosis (IPF), a type of chronic lung disease. ROCK2 has been developed to treat non-alcoholic liver disease, while it is also targeting Crohn’s Disease-related fibrosis.

RXC004

After a false start, Redx is resuming its phase I clinical trial. The trial is split in two: phases Ia and Ib. The former is focused on finding the safest most effective dose, while the latter will seek efficacy data.  The phase Ia will take place over the next 12-18 months, working with advanced cancer patients. The lead investigator is Dr Natalie Cook, of the Christie Hospital, Manchester. The other centres are The Marsden and Guys (London), Oxford and Newcastle.

Value kickers

  • RXC004 Ib-ready in the first-half of next year
  • Fibrosis treatments target significant commercial markets
  • Phase 1-ready idiopathic pulmonary fibrosis candidate ready to enter clinic in the next year

View full REDX profile View Profile

Redx Pharma Plc Timeline

Related Articles

Cyrptocurrencies
June 27 2018
Lancor Scientific is aiming to carry out an initial coin offering by issuing Medici, a new currency based on Ethereum to help Tumour Trace to fund further development
Empty lab
September 19 2018
Management has made some tough decisions, cutting the cost base, since a disappointing first-half performance and expects the benefits to really kick in next year
dna strand
May 08 2019
The latest update reveals the company significant clinical and commercial milestones in sight

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use